164 related articles for article (PubMed ID: 36541733)
21. Clinical and analytical performance of the CLART HPV 4S assay with SurePath screening samples from the Danish cervical cancer screening program using the VALGENT framework.
Ejegod DM; Pedersen H; Quint W; Xu L; Arbyn M; Bonde JH
J Virol Methods; 2021 Jun; 292():114118. PubMed ID: 33766660
[TBL] [Abstract][Full Text] [Related]
22. Alinity m HR HPV Assay Fulfills Criteria for Human Papillomavirus Test Requirements in Cervical Cancer Screening Settings.
Oštrbenk Valenčak A; Šterbenc A; Seme K; Poljak M
J Clin Microbiol; 2019 Dec; 58(1):. PubMed ID: 31666369
[TBL] [Abstract][Full Text] [Related]
23. Clinical validation of Anyplex™ II HPV HR Detection according to the guidelines for HPV test requirements for cervical cancer screening.
Hesselink AT; Sahli R; Berkhof J; Snijders PJ; van der Salm ML; Agard D; Bleeker MC; Heideman DA
J Clin Virol; 2016 Mar; 76():36-9. PubMed ID: 26809131
[TBL] [Abstract][Full Text] [Related]
24. Clinical and analytical performance of the PapilloCheck HPV-Screening assay using the VALGENT framework.
Heard I; Cuschieri K; Geraets DT; Quint W; Arbyn M
J Clin Virol; 2016 Aug; 81():6-11. PubMed ID: 27262102
[TBL] [Abstract][Full Text] [Related]
25. Evaluation of HarmoniaHPV test for detection of clinically significant Human Papillomavirus infection using the VALGENT framework.
Bhatia R; Boada EA; Bonde J; Quint W; Christiansen IK; Xu L; Ejegod DM; Moncur S; Cuschieri K; Arbyn M
J Virol Methods; 2021 Aug; 294():114161. PubMed ID: 33895238
[TBL] [Abstract][Full Text] [Related]
26. Validation of intra- and inter-laboratory reproducibility of the Xpert HPV assay according to the international guidelines for cervical cancer screening.
Akbari A; Vanden Broeck D; Benoy I; Padalko E; Bogers J; Arbyn M
Virol J; 2018 Oct; 15(1):166. PubMed ID: 30373616
[TBL] [Abstract][Full Text] [Related]
27. AmpFire HPV and ScreenFire RS HPV validation trial.
Hou J; Belinson JL; Du H; Li C; Zhang W; Zhang L; Zhang Y; Qu X; Wu R
Am J Clin Pathol; 2024 Jun; 161(6):535-542. PubMed ID: 38365314
[TBL] [Abstract][Full Text] [Related]
28. Which high-risk HPV assays fulfil criteria for use in primary cervical cancer screening?
Arbyn M; Snijders PJ; Meijer CJ; Berkhof J; Cuschieri K; Kocjan BJ; Poljak M
Clin Microbiol Infect; 2015 Sep; 21(9):817-26. PubMed ID: 25936581
[TBL] [Abstract][Full Text] [Related]
29. Clinical validation of full genotyping CLART® HPV4S assay on SurePath and ThinPrep collected screening samples according to the international guidelines for human papillomavirus test requirements for cervical screening.
Ejegod DM; Lagheden C; Bhatia R; Pedersen H; Boada EA; Sundström K; Cortés J; Josë FXB; Cuschieri K; Dillner J; Bonde J
BMC Cancer; 2020 May; 20(1):396. PubMed ID: 32375689
[TBL] [Abstract][Full Text] [Related]
30. Allplex HPV HR Detection assay fulfils all clinical performance and reproducibility validation requirements for primary cervical cancer screening.
Oštrbenk Valenčak A; Cuschieri K; Connor L; Zore A; Smrkolj Š; Poljak M
J Clin Virol; 2024 Feb; 170():105638. PubMed ID: 38183829
[TBL] [Abstract][Full Text] [Related]
31. The Valgent4 protocol: Robust analytical and clinical validation of 11 HPV assays with genotyping on cervical samples collected in SurePath medium.
Bonde J; Ejegod DM; Cuschieri K; Dillner J; Heideman DAM; Quint W; Pavon Ribas MA; Padalko E; Christiansen IK; Xu L; Arbyn M
J Clin Virol; 2018 Nov; 108():64-71. PubMed ID: 30253376
[TBL] [Abstract][Full Text] [Related]
32. Comparing triage algorithms using HPV DNA genotyping, HPV E7 mRNA detection and cytology in high-risk HPV DNA-positive women.
Luttmer R; Berkhof J; Dijkstra MG; van Kemenade FJ; Snijders PJ; Heideman DA; Meijer CJ
J Clin Virol; 2015 Jun; 67():59-66. PubMed ID: 25959161
[TBL] [Abstract][Full Text] [Related]
33. Clinical evaluation of a GP5+/6+-based luminex assay having full high-risk human papillomavirus genotyping capability and an internal control.
Geraets DT; Cuschieri K; de Koning MN; van Doorn LJ; Snijders PJ; Meijer CJ; Quint WG; Arbyn M
J Clin Microbiol; 2014 Nov; 52(11):3996-4002. PubMed ID: 25210073
[TBL] [Abstract][Full Text] [Related]
34. Validation of the clinical performance and reproducibility of the NeuMoDx HPV assay self-sample workflow.
Heideman DAM; Berkhof J; Verhoef L; Ouwerkerk C; Smit PW; Oštrbenk Valenčak A; Mlakar J; Poljak M; Steenbergen RDM; Bleeker MCG
J Clin Virol; 2024 Apr; 171():105649. PubMed ID: 38335717
[TBL] [Abstract][Full Text] [Related]
35. Clinical validation of full HR-HPV genotyping HPV Selfy assay according to the international guidelines for HPV test requirements for cervical cancer screening on clinician-collected and self-collected samples.
Avian A; Clemente N; Mauro E; Isidoro E; Di Napoli M; Dudine S; Del Fabro A; Morini S; Perin T; Giudici F; Cammisuli T; Foschi N; Mocenigo M; Montrone M; Modena C; Polenghi M; Puzzi L; Tomaic V; Valenti G; Sola R; Zanolla S; Vogrig E; Riva E; Angeletti S; Ciccozzi M; Castriciano S; Pachetti M; Petti M; Centonze S; Gerin D; Banks L; Marini B; Canzonieri V; Sopracordevole F; Zanconati F; Ippodrino R
J Transl Med; 2022 May; 20(1):231. PubMed ID: 35581584
[TBL] [Abstract][Full Text] [Related]
36. Concordance of Anyplex™ II HPV HR assays with reference HPV assays in cervical cancer screening: Systematic review.
Biazin H
J Virol Methods; 2022 Mar; 301():114435. PubMed ID: 34919974
[TBL] [Abstract][Full Text] [Related]
37. Intra- and interlaboratory reproducibility of the RIATOL qPCR HPV genotyping assay.
Dhillon SK; Chung PYJ; Padalko E; Praet M; Pereira AR; Redzic N; Vanden Broeck D; Arbyn M
J Med Virol; 2023 Sep; 95(9):e29093. PubMed ID: 37702556
[TBL] [Abstract][Full Text] [Related]
38. PCR-reverse dot blot human papillomavirus genotyping as a primary screening test for cervical cancer in a hospital-based cohort.
Kang Y; Sun P; Mao X; Dong B; Ruan G; Chen L
J Gynecol Oncol; 2019 May; 30(3):e29. PubMed ID: 30887754
[TBL] [Abstract][Full Text] [Related]
39. Accuracy and effectiveness of HPV mRNA testing in cervical cancer screening: a systematic review and meta-analysis.
Arbyn M; Simon M; de Sanjosé S; Clarke MA; Poljak M; Rezhake R; Berkhof J; Nyaga V; Gultekin M; Canfell K; Wentzensen N
Lancet Oncol; 2022 Jul; 23(7):950-960. PubMed ID: 35709810
[TBL] [Abstract][Full Text] [Related]
40. Risk stratification for cervical precancer and cancer by DH3-HPV partial genotyping and cytology in women attending cervical screening: A retrospective cohort study.
Fu Y; Li Y; Li X; Wang X; Lü W
J Med Virol; 2023 Feb; 95(2):e28482. PubMed ID: 36609841
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
